ClinicalTrials.gg
CompletedNCT01764022Updated Nov 29, 2018Results posted

A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

A Phase 3 interventional study of Trastuzumab and Paclitaxel in Human Epithelial Receptor (HER)-2 Positive Breast Cancer, sponsored by Biocad. Completed at 36 sites in 4 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
70th of 366
225 · median 61
Started
2012
with 4 others
Phase 3
60 of 374
3 open now
Registered
188th of 374
by date

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 70th largest by enrollment of the 366 interventional ones that give a count, is one of 5 that started in 2012, is one of 60 in phase 3, and was the 188th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

BCD-022-02 is a double-blind randomized clinical trial comparing efficacy of BCD-022 (INN: trastuzumab) and paclitaxel to Herceptin and paclitaxel in HER2-positive metastatic breast cancer with pharmacokinetics substudy. The purpose of the study is to demonstrate the non-inferiority of efficacy and safety of BCD-022 compared to Herceptin. Also study includes pharmacokinetics assessment.

Read the detailed description

The study is based on the hypothesis of equivalence of BCD-022 (trastuzumab by JSC BIOCAD, Russia) in combination with paclitaxel used as the therapy of inoperable or metastatic HER2(+) breast cancer in comparison with Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in combination with paclitaxel. The objectives of the study is to evaluate efficacy, safety and pharmacokinetics of BCD-022 compared with reference trastuzumab by 1. overall response rate and other efficacy parameters; 2. incidence and severity of adverse events; 3. serum concentration after the first and multiple trastuzumab administration; 4. incidence and concentration of anti-trastuzumab antibodies.

03

Conditions studied

  • Human Epithelial Receptor (HER)-2 Positive Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • trastuzumab
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and ability to follow the Protocol procedures;
  • Age from 18 years to 75 years inclusive;
  • Female gender;
  • confirmed breast cancer (BC);
  • BC (stage IV according to TNM classification version 6);
  • Grade 3+ overexpression confirmed by immunohistochemical (IHC) staining or grade 2+ HER2 overexpression accompanied by HER2 gene amplification confirmed by fluorescent hybridization in situ (FISH) ;
  • Documented results of oestrogen and progesterone receptors expression analysis;
  • (ECOG) status 0, 1 or 2, not increasing within 2 weeks prior to randomization;
  • - 20 weeks or more from the moment of randomization;
  • Presence of at least 1 tumour with a size not less than 1 cm (revealed with computed tomography (CT) slice thickness not more than 5 mm). Patients having bone metastasis as the only measurable tumour are not eligible for the trial;
  • Patients of must implement reliable measures during the study treatment, starting 4 weeks prior to inclusion into the trial and until 6 months after the last administration of the study drug.

Exclusion criteria

Exclusion Criteria:

  • Previous anticancer therapy for BC, including cytotoxic chemotherapy, or previous anticancer therapy with signal transduction inhibitors (e.g. lapatinib), biological drugs (e.g. trastuzumab, bevacizumab), experimental (not approved for BC therapy) anticancer drugs. Any previous hormonal therapy is allowed;
  • Disease progression within 6 months after adjuvant and/or anti BC therapy;
  • Surgery, radiation therapy, use of any experimental medications within 4 weeks (28 days) prior to randomization;
  • to paclitaxel and all medications containing polyoxyethylated castor oil, hypersensitivity to dexamethasone, diphenhydramine, ranitidine/cimetidine, recombinant murine proteins, contrast agents or of study medications;
  • BC metastases in central nervous system, progressing or clinically manifested (e.g. cerebral oedema, spinal cord injury), with exception of non-progressing metastases not requiring treatment with glucocorticosteroids and/or anticonvulsants within 4 weeks prior to randomization;
  • Cardiovascular system pathology (congestive heart failure (CHF) stage III-IV according to (NYHA) classification, unstable angina pectoris, myocardial infarction) within 12 months prior to randomization;
  • Uncontrolled hypertension comprising all cases of arterial hypertension when no decrease in blood pressure could be achieved despite treatment with a combination of 3 antihypertensive drugs including one diuretic and non-medicamental correction methods (low salt diet, physical exercise);
  • \<50% according to electrocardiography;
  • Neutrophils ≤1500/mm3;
  • ≤100 000/mm3;
  • ≤90 g/L;
  • Creatinine level ≥ 1.5 × (ULN);
  • level ≥ 1.5 × ULN;
  • Asparagine transferase () and alanine transferase (ALT) levels ≥ 2.5 × ULN (5 × ULN for patients with liver metastases);
  • Alkaline phosphatase level ≥ 5 × ULN;
  • Pregnancy or lactation;
  • Any other concomitant cancer including contralateral breast cancer revealed within 5 years prior to screening, except curatively treated intraductal carcinoma in situ, curatively treated cervical carcinoma in situ or curatively treated basal cell or squamous cell carcinoma;
  • Conditions limiting patient's adherence to protocol requirements (dementia, neurologic or psychiatric disorders, drug addiction, alcoholism and others);
  • Stage II-IV neuropathy according to (CTCAE) v.4.0;
  • Concomitant participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial;
  • Acute or active chronic infections;
  • virus, virus, or syphilis infections;
  • Obstacles in intravenous administration of study drugs
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    BCD-022

    BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).

    Drug: Trastuzumab · Drug: Paclitaxel

  • Active comparator
    Herceptin®

    In this arm patients will receive 6 courses of treatment with Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in combination with paclitaxel. Patients will receive Herceptin® at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).

    Drug: Trastuzumab · Drug: Paclitaxel

Interventions

  • Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).

    Also known as: BCD-022, Herceptin

  • Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).

    Also known as: Taxacad

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

    Time frame: Day 127

  2. Area Under the Curve After the First Test Drug Administration

    Primary outcome measure for pharmacokinetics (PK) substudy. AUC(0-504) of trastuzumab in HER2(+) mBC patients after first administration of BCD-022 with paclitaxel or Herceptin® with paclitaxel.

    Time frame: up to Day 22, after the first trastuzumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h)

Secondary outcomes

  1. Complete Response Rate

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

    Time frame: Day 127

  2. Partial Response Rate

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

    Time frame: Day 127

  3. Stabilization Rate

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

    Time frame: Day 127

  4. Progression Rate

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

    Time frame: Day 127

  5. Treatment Postponed Due to AE/SAE

    Secondary outcome measure for safety evaluation

    Time frame: Day 127

  6. Treatment Discontinuation Due to AE/SAE

    Secondary outcome measure for safety evaluation

    Time frame: Day 127

  7. Occurrence of Neutralizing Anti-trastuzumab Antibodies

    Secondary outcome measure for immunogenicity assessment. Patient was suggested as NAB-positive if neutralizing anti-trastuzumab antibodies were detected at any of the specified timepoints. Total number of NAB-positive patients in each are presented.

    Time frame: Day 1 (before the drug administration), Day 14, 64, 127 and 154

  8. Cmax After the First Test Drug Administration

    Secondary outcome measure for PK substudy. Peak serum concentration of trastuzumab after single administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel

    Time frame: Up to Day 22

  9. Tmax After the First Test Drug Administration

    Secondary outcome measure for PK substudy. Time to reach peak serum concentration of trastuzumab after the first administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel

    Time frame: Up to Day 22

  10. T1/2 After the First Test Drug Administration

    Secondary outcome measure for PK substudy. Half-life period of trastuzumab after the first administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel.

    Time frame: Up to Day 22

  11. Cmax After the Sixth Test Drug Administration

    Secondary outcome measure for PK substudy. Peak serum concentration of trastuzumab after the sixth administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel.

    Time frame: Up to Day 127

  12. Tmax After the Sixth Test Drug Administration

    Secondary outcome measure for PK substudy. Time to reach peak serum concentration of trastuzumab after the sixth administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel

    Time frame: Up to Day 127

07

Results

Posted Oct 24, 2016

Participant flow

Participant flow — Overall Study
MilestoneBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Started115110
Received at least 1 dose of study drug113110
Completed10796
Not completed814
Withdrew: Death35
Withdrew: Withdrawal by subject26
Withdrew: Lack of efficacy01
Withdrew: Physician decision02
Withdrew: Lost to follow-up20
Withdrew: Protocol violation10

Outcome measures

PrimaryOverall Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

Time frame:
Day 127
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Overall Response Rate5648
PrimaryArea Under the Curve After the First Test Drug Administration

Primary outcome measure for pharmacokinetics (PK) substudy. AUC(0-504) of trastuzumab in HER2(+) mBC patients after first administration of BCD-022 with paclitaxel or Herceptin® with paclitaxel.

Time frame:
up to Day 22, after the first trastuzumab administration (time points for blood samples: 0 h 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h)
Reported as:
Median · (ng/ml)*hour
Area Under the Curve After the First Test Drug Administration
(ng/ml)*hourBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Area Under the Curve After the First Test Drug Administration28969372.5 (20165337.0 to 36096712.5)28796527.9 (20430685.5 to 36232918.5)
SecondaryComplete Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

Time frame:
Day 127
Reported as:
Count of participants · Participants
Complete Response Rate
ParticipantsBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Complete Response Rate42
SecondaryPartial Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

Time frame:
Day 127
Reported as:
Count of participants · Participants
Partial Response Rate
ParticipantsBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Partial Response Rate5246
SecondaryStabilization Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

Time frame:
Day 127
Reported as:
Count of participants · Participants
Stabilization Rate
ParticipantsBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Stabilization Rate2821
SecondaryProgression Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The response was assessed at the screening, after 3 therapy cycles and after 6 therapy cycles. If CT after 3 or 6 therapy cycles revealed the complete or partial response, a confirmatory CT scan was performed 4 weeks later. The best response during the study was assessed.

Time frame:
Day 127
Reported as:
Count of participants · Participants
Progression Rate
ParticipantsBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Progression Rate2528
SecondaryTreatment Postponed Due to AE/SAE

Secondary outcome measure for safety evaluation

Time frame:
Day 127
Reported as:
Number · participants
Treatment Postponed Due to AE/SAE
participantsBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Treatment Postponed Due to AE/SAE45
SecondaryTreatment Discontinuation Due to AE/SAE

Secondary outcome measure for safety evaluation

Time frame:
Day 127
Reported as:
Number · participants
Treatment Discontinuation Due to AE/SAE
participantsBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Treatment Discontinuation Due to AE/SAE01
SecondaryOccurrence of Neutralizing Anti-trastuzumab Antibodies

Secondary outcome measure for immunogenicity assessment. Patient was suggested as NAB-positive if neutralizing anti-trastuzumab antibodies were detected at any of the specified timepoints. Total number of NAB-positive patients in each are presented.

Time frame:
Day 1 (before the drug administration), Day 14, 64, 127 and 154
Reported as:
Number · participants
Occurrence of Neutralizing Anti-trastuzumab Antibodies
participantsBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Occurrence of Neutralizing Anti-trastuzumab Antibodies34
SecondaryCmax After the First Test Drug Administration

Secondary outcome measure for PK substudy. Peak serum concentration of trastuzumab after single administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel

Time frame:
Up to Day 22
Reported as:
Median · ng/ml
Cmax After the First Test Drug Administration
ng/mlBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Cmax After the First Test Drug Administration218720.0 (178270.0 to 264700.0)216710.0 (186740.0 to 269780.0)
SecondaryTmax After the First Test Drug Administration

Secondary outcome measure for PK substudy. Time to reach peak serum concentration of trastuzumab after the first administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel

Time frame:
Up to Day 22
Reported as:
Median · hours
Tmax After the First Test Drug Administration
hoursBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Tmax After the First Test Drug Administration160.6 (103.2 to 207.6)162.1 (101.9 to 201.6)
SecondaryT1/2 After the First Test Drug Administration

Secondary outcome measure for PK substudy. Half-life period of trastuzumab after the first administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel.

Time frame:
Up to Day 22
Reported as:
Median · hours
T1/2 After the First Test Drug Administration
hoursHerceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)BCD-022 (CJSC BIOCAD)
T1/2 After the First Test Drug Administration162.1 (101.9 to 201.6)160.6 (103.2 to 207.6)
SecondaryCmax After the Sixth Test Drug Administration

Secondary outcome measure for PK substudy. Peak serum concentration of trastuzumab after the sixth administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel.

Time frame:
Up to Day 127
Reported as:
Median · ng/ml
Cmax After the Sixth Test Drug Administration
ng/mlBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Cmax After the Sixth Test Drug Administration168735.0 (148810.0 to 204870.0)169220.0 (150140.0 to 179230.0)
SecondaryTmax After the Sixth Test Drug Administration

Secondary outcome measure for PK substudy. Time to reach peak serum concentration of trastuzumab after the sixth administration of BCD-022 + paclitaxel or Herceptin® + paclitaxel

Time frame:
Up to Day 127
Reported as:
Median · hour
Tmax After the Sixth Test Drug Administration
hourBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Tmax After the Sixth Test Drug Administration185.8 (146.3 to 237.1)192.9 (137.9 to 237.1)

Adverse events

Collected over up to 154 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCD-022 (CJSC BIOCAD)3/113 (2.7%)8/113 (7.1%)106/113 (93.8%)
Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)5/110 (4.5%)13/110 (11.8%)104/110 (94.5%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
Disease progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1132/110
Paroxism of atrial fibrillationCardiac disorders0/1132/110
Non-Neutropenic FeverGeneral disorders0/1132/110
Death for unknown reasonGeneral disorders1/1131/110
Febrile neutropeniaBlood and lymphatic system disorders0/1131/110
Ventricular extrasystolone RYAN-1Cardiac disorders0/1131/110
Anemia with trombocytopeniaBlood and lymphatic system disorders0/1131/110
Diarrhea with vomiting and weaknessGeneral disorders0/1131/110
Pneumonitis with SepticemiaInfections and infestations0/1131/110
Aspiration pneumoniaRespiratory, thoracic and mediastinal disorders0/1131/110
Most frequent other events
Showing 10 of 32
Most frequent other events
EventBCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)
AnemiaBlood and lymphatic system disorders75/11373/110
NeutropeniaBlood and lymphatic system disorders66/11356/110
LeucopeniaBlood and lymphatic system disorders64/11354/110
LymphopeniaBlood and lymphatic system disorders53/11340/110
HyperglycemiaMetabolism and nutrition disorders39/11347/110
LeucocytosisBlood and lymphatic system disorders24/11335/110
Elevated lactate degydrohenaseInvestigations34/11332/110
Elevated absolute neutrophil countBlood and lymphatic system disorders26/11329/110
Elevated ASTHepatobiliary disorders29/11326/110
Elevated alkaline phosphotaseHepatobiliary disorders28/11327/110

Baseline characteristics

223 of 225 randomized patients received at least one BCD-022 or Herceptin® injection. 2 patients were excluded prior to first drug administration. Patients who do not received at least one study drug administration were not included to any analysis.

Age, Continuous
Age, Continuous(years)BCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)Total
Mean50.687 ± 10.94850.573 ± 9.87750.63 ± 10.415
Sex: Female, Male
Sex: Female, Male(Participants)BCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)Total
Female115110225
Male000
HER2 Expression
HER2 Expression(Participants)BCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)Total
HER2 +++10097197
HER2 ++141327
Unknown101
Histologic type of cancer
Histologic type of cancer(Participants)BCD-022 (CJSC BIOCAD)Herceptin ® (F. Hoffmann-La Roche Ltd., Switzerland)Total
Ductal363369
Medullar347
Lobular231841
Tubular353772
Mucinouse358
Micropapillary101
Unknown histilogic type141327
08

Study locations

36 sites
  • Brest Region Clinical Oncology Dispensary
    Brest, Belarus
  • Gomel Region Clinical Oncology Dispensary
    Gomel, Belarus
  • Grodno Regional Hospital
    Grodno, Belarus
  • Vitebsk State Medical University of Order of Peoples' Friendship
    Vitebsk, Belarus
  • HCG Bangalore Institute of Oncology
    Bangalore, 560027, India
  • M.S.Ramaiah Memorial Hospital
    Bangalore, 560054, India
  • Narayana Hrudayalaya Hospitals
    Bangalore, 560099, India
  • State Health Institution of Moscow "Moscow City Oncology Hospital #62 of Moscow Board of Health"
    Stepanovskoye, Moscow Region 143423, Russian Federation
  • Arkhangelsk District Clinical Oncology Dispensary
    Arkhangelsk, 163045, Russian Federation
  • Non-governmental Healthcare Institution "Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways"
    Chelyabinsk, 355047, Russian Federation
  • State-financed Health Institution "Chelyabinsk Region Clinical Oncology Dispansary"
    Chelyabinsk, 454087, Russian Federation
  • State-financed Health Institution "Republican Clinical Oncology Hospital"
    Izhevsk, 426009, Russian Federation
  • Institution of Russian Academy of Medical Sciences "Russian Cancer Research Center named after N.N. Blokhin"
    Moscow, 115478, Russian Federation
  • Federal State Institution "Moscow Institute of Cancer Research named after P.A. Hertsen" Ministry of Health of Russian Federation
    Moscow, 125284, Russian Federation
  • Regional State Health Institution "Orlov Oncology Dispansary"
    Orel, 302020, Russian Federation
  • State Health Institution "Region Oncology Dispansary"
    Penza, 440071, Russian Federation
  • Perm Region Oncology Dispensary
    Perm, 614066, Russian Federation
  • Federal Government Budgetary Institution "Rostov Institute of Cancer Research" of Ministry of Health of Russian Federation
    Rostov-on-Don, 314019, Russian Federation
  • Saint Petersburg City Clinical Oncology Center
    Saint Petersburg, 197022, Russian Federation
  • State-financed Health Institution "Samara Region Clinical Oncology Dispansary"
    Samara, 443031, Russian Federation
  • Oncology Dispensary 2
    Sochi, 354057, Russian Federation
  • Military Medical Academy named after S.M. Kirov
    St.Petersburg, 194044, Russian Federation
  • N.N.Petrov Oncology Research Center
    St.Petersburg, 197758, Russian Federation
  • Russian scientific center of radiology and surgery technologies
    St.Petersburg, Russian Federation
  • State-financed Health Institution "Stavropol Region Clinical Oncology Dispansary"
    Stavropol, 355047, Russian Federation
  • Republican Clinical Oncology Dispensary of Ministry of Health republic Bashkortostan
    Ufa, 450054, Russian Federation
  • Volgograd District Oncology Dispensary №1
    Volgograd, 400138, Russian Federation
  • Donetsk City Oncology Dispensary
    Donetsk, Ukraine
  • Donetsk Regional Antitumor Center
    Donetsk, Ukraine
  • Kharkiv Regional Clinical Oncology Center
    Kharkiv, Ukraine
  • Kryvyi Rih Oncology Dispensary
    Kryvyi Rih, Ukraine
  • Lviv Regional State Cancer Diagnostics and Treatment Center
    Lviv, Ukraine
  • City Hospital №2
    Makiivka, Ukraine
  • Poltava Regional Clinical Oncology Dispensary
    Poltava, Ukraine
  • Zakarpatskyi Regional Clinical Oncology Center
    Uzhhorod, Ukraine
  • Vinnytsia Regional Clinical Oncology Dispensary
    Vinnytsia, Ukraine
09

References and documents

Publications

  • Alexeev SM, Khorinko AV, Mukhametshina GZ, Shelepen KG, Burdaeva ON, Kulik SA, Satheesh CT, Srivastava K, Vikranth M, Kryukov F, Paltusova AN, Shustova MS, Ivanov RA. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab. BMC Cancer. 2020 Aug 20;20(1):783. doi: 10.1186/s12885-020-07247-9. PubMed 32819305 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Mar 2015 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2013
First posted
Jan 9, 2013
Start
Oct 2012
Primary completionActual
Mar 2015
CompletionActual
Dec 2017
Results first posted
Oct 24, 2016
Last update
Nov 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01764022
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Jan 9, 2013
Start date
Oct 2012
Primary completion
Mar 2015
Completion
Dec 2017
Results posted
Oct 24, 2016
Last update
Nov 29, 2018

Study contacts

Roman Ivanov, MD, PhD
study chair · Vice-president, R&D

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab · Paclitaxel

Start the discussion